AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23726516 — intervention group
Group type: COMPARATOR
Intervention: Neutral vignette
Number of subjects: 116
Study 21684391 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor arm (dedicated HIV counselors)
Number of subjects: 4855
Study 21684391 — intervention group
Group type: COMPARATOR
Intervention: Provider arm (ED staff)
Number of subjects: 4855
Study 18279106 — intervention group
Group type: EXPERIMENTAL
Intervention: Locteron 320 microg
Number of subjects: 27
Study 18279106 — intervention group
Group type: EXPERIMENTAL
Intervention: Locteron 80 microg
Number of subjects: 27
Study 18279106 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha2b 80 microg
Number of subjects: 27
Study 18279106 — intervention group
Group type: EXPERIMENTAL
Intervention: Locteron 20 microg and 80 microg
Number of subjects: 27
Study 17146981 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive allocation treatment
Number of subjects: 0
Study 17146981 — intervention group
Group type: COMPARATOR
Intervention: Existing rules
Number of subjects: 0
Study 15339529 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 15339529 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus opium
Number of subjects: 0
Study 15339529 — intervention group
Group type: EXPERIMENTAL
Intervention: Opium plus buprenorphine
Number of subjects: 0
Study 15339529 — intervention group
Group type: EXPERIMENTAL
Intervention: Opium plus Han's instrument
Number of subjects: 0
Study 11256775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (120 IU/kg twice daily)
Number of subjects: 1128
Study 11256775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (7,500 IU)
Number of subjects: 1128
Study 11256775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1128
Study 9167318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 149
Study 9167318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 149
Study 9167318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus cognitive behaviour therapy
Number of subjects: 149
Study 9167318 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cognitive behaviour therapy
Number of subjects: 149
Study 9167318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy alone
Number of subjects: 149
Study 9167318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 8245990 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin anticoagulation (6-12 weeks course)
Number of subjects: 174
Study 8245990 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation (control group)
Number of subjects: 174
Study 3766365 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cardiac counseling and type A behavioral counseling (592 participants)
Number of subjects: 1013
Study 3766365 — intervention group
Group type: COMPARATOR
Intervention: Group cardiac counseling (270 participants)
Number of subjects: 1013
Study 3766365 — intervention group
Group type: COMPARATOR
Intervention: No counseling (comparison group of 151 participants)
Number of subjects: 1013
Study 3766365 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (592 participants)
Number of subjects: 1013
Study 3766365 — intervention group
Group type: COMPARATOR
Intervention: Control group (270 participants)
Number of subjects: 1013
Study 31712335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored and collaborative support for ACCHSs (early support)
Number of subjects: 22
Study 31712335 — intervention group
Group type: COMPARATOR
Intervention: Wait-control (late support)
Number of subjects: 22
Study 31712335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored support elements including training and feedback
Number of subjects: 22
Study 29609153 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 97
Study 29609153 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 97
Study 26812515 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training plus nutritional supplementation (R/N group)
Number of subjects: 39
Study 26812515 — intervention group
Group type: COMPARATOR
Intervention: Resistance training alone (R group)
Number of subjects: 39
Study 24448644 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (0.75, 1.5 mg/kg)
Number of subjects: 65
Study 24448644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20 or 40 IU)
Number of subjects: 65
Study 24448644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 23140055 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion-20 min
Number of subjects: 84
Study 23140055 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion-40 min
Number of subjects: 84
Study 23140055 — intervention group
Group type: COMPARATOR
Intervention: Medication (Ranitidine)
Number of subjects: 84
Study 23140055 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion-20 min (1 month follow-up)
Number of subjects: 84
Study 23140055 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion-40 min (1 month follow-up)
Number of subjects: 84
Study 23140055 — intervention group
Group type: COMPARATOR
Intervention: Medication (Ranitidine) (1 month follow-up)
Number of subjects: 84
Study 20516228 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaled response format
Number of subjects: 0
Study 20516228 — intervention group
Group type: COMPARATOR
Intervention: Dichotomous categorical response
Number of subjects: 0
Study 20516228 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency information followed by abstract conditional reasoning problems
Number of subjects: 0
Study 20516228 — intervention group
Group type: COMPARATOR
Intervention: Scaled response condition
Number of subjects: 0
Study 19227193 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (male and female)
Number of subjects: 14
Study 19227193 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of vibration
Number of subjects: 14
Study 19227193 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen text/background colour
Number of subjects: 14
Study 19227193 — intervention group
Group type: EXPERIMENTAL
Intervention: Second order interaction (gender, vibration, colour)
Number of subjects: 14
Study 16162054 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referenced feedback and n Ach
Number of subjects: 0
Study 16162054 — intervention group
Group type: EXPERIMENTAL
Intervention: Norm-referenced feedback and san Ach
Number of subjects: 0
Study 16162054 — intervention group
Group type: EXPERIMENTAL
Intervention: n Ach and san Ach
Number of subjects: 0
Study 12552508 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 1.2 g twice a day for 4 weeks
Number of subjects: 38
Study 12552508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 10651655 — intervention group
Group type: EXPERIMENTAL
Intervention: Eudragit-coated gelatine capsule containing 111In-labelled amberlite resin
Number of subjects: 10
Study 9007589 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg on the first day then 200 mg)
Number of subjects: 72
Study 9007589 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B/5-flucytosine (1.0-1.5 mg/kg body weight every other day and 3 x 2.5 g flucytosine/day)
Number of subjects: 72
Study 9007589 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B/5-flucytosine
Number of subjects: 72
Study 9007589 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 72
Study 1503286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygrophobic filter (Pall, Ultipor)
Number of subjects: 75
Study 1503286 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifier (Dräger, Aquapor)
Number of subjects: 75
Study 1503286 — intervention group
Group type: COMPARATOR
Intervention: No warming device (Control group A)
Number of subjects: 75
Study 6094438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (50 mg/kg/dose every 6 h for 10 to 14 days)
Number of subjects: 30
Study 6094438 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin and chloramphenicol (standard doses)
Number of subjects: 30
Study 31362183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasal application)
Number of subjects: 13
Study 31362183 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 13
Study 31362183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 13
Study 29347866 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose-bar
Number of subjects: 0
Study 29347866 — intervention group
Group type: COMPARATOR
Intervention: Control-bar
Number of subjects: 0
Study 26964689 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat breakfast (60% energy from fat)
Number of subjects: 32
Study 26964689 — intervention group
Group type: COMPARATOR
Intervention: Low-fat breakfast (20% energy from fat)
Number of subjects: 32
Study 26964689 — intervention group
Group type: COMPARATOR
Intervention: Macronutrient balanced breakfast (33% energy from fat)
Number of subjects: 32
Study 25010881 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mixed with irreversible hydrocolloid
Number of subjects: 20
Study 25010881 — intervention group
Group type: COMPARATOR
Intervention: Water mixed with irreversible hydrocolloid
Number of subjects: 20
Study 22809972 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 58
Study 22809972 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 58
Study 21294410 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection paravertebral block (PVB) with 0.3 ml/kg of 0.5% plain bupivacaine at T4 paravertebral space followed by general anesthesia
Number of subjects: 20
Study 21294410 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (Control)
Number of subjects: 20
Study 18021336 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel 20 mg/kg alone
Number of subjects: 10
Study 18021336 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 20 mg/kg with ketoconazole 400 mg daily for 5 days
Number of subjects: 10
Study 15863438 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson A breathing system with a fresh gas flow of 9 litre min(‐1) (group A9)
Number of subjects: 65
Study 15863438 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson D system with a fresh flow of 6 litre min(‐1) (group D6)
Number of subjects: 65
Study 15863438 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson D system with a fresh flow of 3 litre min(‐1) (group D3)
Number of subjects: 65
Study 11911101 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution intake during labour
Number of subjects: 201
Study 11911101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 201
Study 9866670 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended levels of antidepressant treatment (doses recommended by the Agency for Health Care Policy and Research for 90 days or more)
Number of subjects: 358
Study 9866670 — intervention group
Group type: COMPARATOR
Intervention: Less-than-recommended levels of antidepressant treatment
Number of subjects: 358
Study 9866670 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum recommended levels of antidepressant treatment
Number of subjects: 358
Study 7533825 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) - lenograstim 5 micrograms/kg/d between cycles
Number of subjects: 65
Study 7533825 — intervention group
Group type: COMPARATOR
Intervention: Control - VICE chemotherapy alone
Number of subjects: 65
Study 2240750 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 91
Study 2240750 — intervention group
Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 91
Study 388083 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin chemotherapy
Number of subjects: 29
Study 388083 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 29
Study 388083 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 29
Study 30528166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise training
Number of subjects: 48
Study 30528166 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise training
Number of subjects: 48
Study 26884620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (0.2 mg/kg bolus followed by 0.2 mg/kg/h for 24 h)
Number of subjects: 106
Study 26884620 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 106
Study 25759407 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS impulses at a strong but comfortable amplitude (median pulse amplitude 20 mA)
Number of subjects: 70
Study 25759407 — intervention group
Group type: COMPARATOR
Intervention: TENS impulses just above the sensory threshold (median pulse amplitude 7 mA)
Number of subjects: 70
Study 23415433 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple pectin
Number of subjects: 100
Study 23415433 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 100
Study 23415433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21812260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianwang buxin decoction (TWBXD) combined with dormancy hygiene education (DHE)
Number of subjects: 101
Study 21812260 — intervention group
Group type: COMPARATOR
Intervention: Tianwang buxin decoction (TWBXD) alone
Number of subjects: 101
Study 19748409 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: high-velocity low-amplitude manipulation, high-voltage pulse galvanic stimulation, counterforce bracing, ice, and exercises
Number of subjects: 6
Study 19748409 — intervention group
Group type: COMPARATOR
Intervention: Group B: ultrasound, counterforce bracing, and exercise
Number of subjects: 6
Study 16908918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse management
Number of subjects: 406
Study 16908918 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 406
Study 15128005 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 0
Study 15128005 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 0
Study 15128005 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative surgical margins
Number of subjects: 0
Study 15128005 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-breast irradiation
Number of subjects: 0
Study 15128005 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Number of subjects: 0
Study 15128005 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0
Study 11888823 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (320mgI.ml(‐1))
Number of subjects: 10
Study 11888823 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide (300mgI.ml(‐1))
Number of subjects: 10
Study 11888823 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic saline (10ml)
Number of subjects: 10
Study 11888823 — intervention group
Group type: COMPARATOR
Intervention: Iodixanol and Iopromide
Number of subjects: 10
Study 9598509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with a gonadotropin‐releasing hormone agonist for 3 months before radical prostatectomy
Number of subjects: 122
Study 9598509 — intervention group
Group type: COMPARATOR
Intervention: Radical retropubic prostatectomy only (no pretreatment)
Number of subjects: 122
Study 9598509 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative surgical margin
Number of subjects: 122
Study 9598509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal pretreatment
Number of subjects: 122
Study 9598509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal pretreatment and radical prostatectomy
Number of subjects: 122
Study 7934431 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (16 mg, subcutaneous administration)
Number of subjects: 24
Study 7934431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3793199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine (6 micrograms/kg)
Number of subjects: 20
Study 3793199 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (0.3 mg/kg)
Number of subjects: 20
Study 31289064 — intervention group
Group type: EXPERIMENTAL
Intervention: E+PBP (national e-learning programme plus PBP simulation)
Number of subjects: 90
Study 31289064 — intervention group
Group type: COMPARATOR
Intervention: E (national NEWS e-learning programme only)
Number of subjects: 90
Study 31289064 — intervention group
Group type: COMPARATOR
Intervention: E+S (national e-learning programme plus standard simulation)
Number of subjects: 90
Study 27555097 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 38
Study 27555097 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary, group-based medical diabetes and weight management program
Number of subjects: 38
Study 26004393 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 administration for more than 1 year
Number of subjects: 89
Study 26004393 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 administration periods of 24 months or longer
Number of subjects: 89
Study 26004393 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 administration
Number of subjects: 89
Study 23452670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 5
Study 23452670 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric arc therapy (VMAT)
Number of subjects: 5
Study 23452670 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomotherapy (TOMO)
Number of subjects: 5
Study 23452670 — intervention group
Group type: COMPARATOR
Intervention: VMAT (normalized by IMRT)
Number of subjects: 5
Study 23452670 — intervention group
Group type: COMPARATOR
Intervention: TOMO (normalized by IMRT)
Number of subjects: 5
Study 21252828 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 84
Study 21252828 — intervention group
Group type: COMPARATOR
Intervention: Open donor nephrectomy (ODN)
Number of subjects: 84
Study 19307517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D (with or without calcium)
Number of subjects: 42279
Study 19307517 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of oral vitamin D (>400 IU/d)
Number of subjects: 42279
Study 16870768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tefibazumab (20 mg/kg as a single infusion)
Number of subjects: 60
Study 16870768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14997746 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation treatment
Number of subjects: 0
Study 14997746 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 14997746 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation treatment in ductal carcinoma in situ
Number of subjects: 0
Study 14997746 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 14997746 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient selection for breast conservation without radiation
Number of subjects: 0
Study 11607948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy and massage (AM)
Number of subjects: 21
Study 11607948 — intervention group
Group type: COMPARATOR
Intervention: Conversation and aromatherapy (CA)
Number of subjects: 21
Study 11607948 — intervention group
Group type: COMPARATOR
Intervention: Massage only (M)
Number of subjects: 21
Study 9476185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, prescribed to 73.9% of patients receiving treatment.
Number of subjects: 3685
Study 9476185 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment motivated by fear of stress mucosal lesions (28%) and therapy with other drugs (56%).
Number of subjects: 3685
Study 9476185 — intervention group
Group type: EXPERIMENTAL
Intervention: General prescription practices for peptic diseases.
Number of subjects: 3685
Study 7705196 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 17
Study 7705196 — intervention group
Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 17
Study 2959623 — intervention group
Group type: EXPERIMENTAL
Intervention: GTF vaccine with aluminum phosphate (AP)
Number of subjects: 25
Study 2959623 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate buffer with aluminum phosphate (AP) (Control)
Number of subjects: 25
Study 28097476 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 12 weeks
Number of subjects: 23
Study 28097476 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) groups
Number of subjects: 23
Study 26995403 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography
Number of subjects: 10003
Study 26995403 — intervention group
Group type: COMPARATOR
Intervention: Functional Testing
Number of subjects: 10003
Study 24731231 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous glutamine supplementation (L-alanyl-L-glutamine, 0.28 g/kg during 20 hours)
Number of subjects: 11
Study 24731231 — intervention group
Group type: COMPARATOR
Intervention: Basal measurements without supplementation
Number of subjects: 11
Study 23529377 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptive message tone
Number of subjects: 1865
Study 23529377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dictated navigation autonomy
Number of subjects: 1865
Study 23529377 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive email reminders
Number of subjects: 1865
Study 23529377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored testimonials
Number of subjects: 1865
Study 19703825 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment
Number of subjects: 177
Study 19703825 — intervention group
Group type: COMPARATOR
Intervention: Empirical treatment
Number of subjects: 177
Study 18940387 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral estradiol valerate
Number of subjects: 73
Study 18940387 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17beta‐estradiol gel
Number of subjects: 73